Clinical Trial Update: Telbivudine Therapy in HBeAg-positive Pregnant Women to Prevent Mother-to-infant Transmission of HBV [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating telbivudine to prevent mother-to-infant transmission of hepatitis B in HBeAg-positive pregnant women; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Telbivudine (telbivudine)

Snippet

Sponsor: Yi-Hua Zhou | Conditions: HBV | Phase 4 | Status: COMPLETED